1 / 48

Inborn errors of Metabolism

Inborn errors of Metabolism. Approach to Diagnosis and management. Defining inborn errors of metabolism. Broad definition: Any defect related to the inappropriate metabolism of substrates essential for an organism’s survival. Defects in energy metabolism

taurus
Télécharger la présentation

Inborn errors of Metabolism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inborn errors of Metabolism Approach to Diagnosis and management

  2. Defining inborn errors of metabolism Broad definition: Any defect related to the inappropriate metabolism of substrates essential for an organism’s survival • Defects in energy metabolism • Defects in protein synthesis or catabolism leading to intoxication with toxic substrates and/or absence of essential metabolic substrates • Synthetic defects – inability to produce an essential structural substrate • Defects in transport of essential components – cystic fibrosis, lysinuric protein deficiency • Defects in detoxifying specific substances • Generalized global tissue dysfunction (mitochondria)

  3. Inborn errors of metabolism:General points Incidence in heterogeneous population 1:750-1000 However, incidence higher if we include hyperlipoproteinemias Heterozygote familial hypercholesterolemia has an incidence of 1:500 Much more common in inbred populations and consanguineous couples Signs and symptoms of metabolic disease are usually non-specific Can present at all ages Underdiagnosis of metabolic diseases but improving with new genetic techniques and improved mass screening

  4. Mortality related to metabolic diseases 120 children aged 0-14 y died in a ten year period of inborn errors of metabolism This was 3.5% of total child mortality and 9.5% of non-acquired (genetic) mortality

  5. Complexity of inborn errors of metabolism

  6. Diagnosing metabolic disease

  7. Approach to diagnosing metabolic disease Genetic testing for specific at risk groups Prevention Screening approach Testing entire population using relatively inexpensive (price/unit) techniques High throughput (180,000 samples/yr/IL) Clinical, biochemical, and molecular analysis of symptomatic patients

  8. Populations at risk • Specific population groups are at greater risk for a disease • Founder effect • Inbreeding • Prevention • Premarital testing • Prenatal testing • Preimplantation genetic diagnosis

  9. Basis for newborn screening Cost-effective Easy/inexpensive method for detecting IEM High throughput methods Rapid turnaround High sensitivity (detect most cases) High specificity (low false positive rate) Effective notification system Possibility for intervention Minimal harm to patient

  10. Newborn screening First introduced for PKU (Guthrie) Ames test Extended to several other diseases including galactosemia, hypothyroidism, sickle cell, thallasemia, congenital adrenal hyperplasia, and homocystinuria More countries and states including Israel are now using tandem mass spectrometry for more extensive evaluation

  11. WHO criteria for screening

  12. Early methods for screening for inborn errors of metabolism Guthrie test Place blood drop on agar plate containing B. subtilis and an inhibitor B-2-thienylalanine High levels of phenylalanine in blood spot overcome inhibition and there is growth Ames test Paper impregnated with ferric chloride which reacts with phenylalanine

  13. Tandem mass spectrometry (MS/MS)

  14. Approximately .3/1000 detection rate

  15. Phenylketonuria Phenylalanine hydroxylase

  16. Phenylketonuria In 1934, Folling discovered that children with mental retardation had high levels of phenylalanine in blood Classic: deficiency in phenylalanine hydroxylase Abnormalities in tone, myoclonic seizures, mental retardation, disorders of pigmentation Incidence: 1;10,000-15,000, Turkey: <1:3000 TX: Dietary – reduction in phenylalanine, provision of tyrosine

  17. CONTROL PKU MSUD

  18. Problems with newborn screening Not all diseases are screened False positive – without disease False negative – disease undetected Some disorders are not disorders Asymptomatic children Unclear treatment recommendations Difficulty in follow-up Privacy issues

  19. Disorders not detected Disorders of carbohydrate metabolism Mitochondrial disorders Steroid disorders and hyperlipidemias Some urea cycle disorders Tissue specific disorders with no blood markers

  20. CASE STUDY: Short chain acyl dehydrogenase (SCAD) deficiency Associated with CNS disease Question of whether this gene should be screened for US vs. Europe High prevalence of 319 C>T mutation among Ashkenazic Jews 1:15 carrier rate, 1:900 homozygotes Should be 2700 cases in Israel but only a handful of symptomatic individuals What type of intervention?

  21. Tay-Sachs Hexoaminidase A deficiency Cerebral and retinal degeneration Cherry red spot (macular) Hypotonia, motor weakness, developmental delay Carrier rate 1:30 in Ashkenazic Jews Screening has led to 90% reduction in Jewish population

  22. Signs of metabolic disease If the child: Looks bad Smells bad Feels bad Tastes bad Sounds bad Think Metabolic

  23. Manifestations of metabolic diseases CNS Neuroanatomic malformations Leigh’s disease Developmental delay, mental retardations Movement disorders Hypotonia, spasticity Altered mental status Seizures Visual disturbances Pigmented retinopathy Deafness

  24. Cardiac Cardiomegaly (Pompe’s disease) Dilated cardiomyopathy Rhythm Disturbances Pulmonary Proteinosis (lysinuric protein intolerance) Insufficiency Frequent pneumonia Tachypnea, Kussmaul breathing (acidosis) Manifestations of metabolic diseases

  25. GI Dysphagia Pseudo-obstruction, diarrhea Bloating Liver Insufficiency Inflammation (increased transaminases) Hyperbilirubinemia Cirrhosis Hepatomegaly (glycogen or fats) Manifestations of metabolic diseases

  26. Renal Insufficiency Storage disease RTA Musculoskeletal Malformations Osteopenia/osteoporosis Weakness Myoglobinuria Contractures Manifestations of metabolic diseases

  27. Skin Nearly all skin disorders including seborrhea, ichthyosis Hematological Anemia (all types) Thrombocytopenia/Leukopenia Pancytopenia Manifestations of metabolic diseases

  28. Manifestations of mitochondrial disease Cardiomyopathy / myopathy Stroke-like episodes, neuroanatomic changes Lactic acidosis, Leigh syndrome Seizures, myoclonues, dystonia, Parkinsonism Diabetes Deafness Chorea, ataxia, encephalomyelopathy Sudden infant death syndrome Ophalmoplegia, optic neuropathy, pigmented retinopathy Nelson, Textbook of Pediatrics, 19th edition, p. 508

  29. Biochemical Hypoglycemia Endocrine disturbances Metabolic acidosis Respiratory acidosis/alkalosis Lactic acidosis Hyperammonemia Hypoalbuminemia Altered coagulation profile Hepatitis profile Manifestations of metabolic diseases

  30. Evaluation of infants with suspected metabolic disorders Primary evaluation Arterial blood gas Glucose CBC and Differential Lactate/pyruvate Urinary reducing substances Serum ammonia Liver function tests PT/PTT NOTE: Very important at this step to rule out other non-metabolic related causes for clinical manifestations

  31. Secondary evaluation Urine organic acids Serum amino acids Total and free plasma carnitine Very long chain fatty acids Fed and fasting lactate and pyruvate Cardiac echo Opthalmologic exam EEG Head CT and/or MRI Evaluation of infants with suspected metabolic disorders

  32. Tertiary evaluation Depends on results of initial evaluation Specific enzyme assays in lymphocytes, fibroblasts or tissue Specialized tests, e.g., CSF glycine or lactate, acylcarnitine profile, glycoprotein electrophoresis Histology, e.g., muscle biopsy, histological staining Mitochondrial studies Activity O2 Uptake DNA analysis Challenge tests – fasting, protein loading Evaluation of infants with suspected metabolic disorders

  33. Genetic analysis • Mutational analysis • When specific defect is known • Reverse genetics • Arrays, chips, genomic scanning, SNPs, • Cost effective • Excellent coverage • Does not always identify correct genetic defect or sole defect • Advantages over the traditional approach

  34. Treatment of metabolic diseases Enzyme replacement Detoxification Urea cycle defects Nutritional support Bypass defect NTBC in tyrosinemia Cofactor treatment Transplantation Genetic therapy Bone marrow Stem cell

  35. Galactosemia Classic disease caused by galactose-1-phosphate uridyl transferase Symptoms after lactose formula or breast feeding Hepatomegaly and jaundice Gram- sepsis Cataracts if untreated Tx: non-lactose containing formula

  36. Tyrosinemia Type 1 Defect in Fumarylacetoacetate hydrolase Hepatic decompensation, coagulopathy, low albumin, cirrhosis, RTA DX: elevated tyrosine, characteristic urine metabolites including succinylacetone Long term – hepatic carcinoma TX: Low tyrosine/phenylalanine diet, treatment with NTBC, a herbicide, which inhibits hydroxyphenyl-pyruvate hydroxylase

More Related